Drug Trial Radar · NCT01744223
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Last checked: Nov 19, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Mar 2013
Primary completion
Oct 9, 2019
Study completion Oct 2032
Sponsor
- Lead sponsor
- Bellicum PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the laboratory and then given back to the patient along with the stem cell transplant (T cell addback), can help the immune system recover faster after the transplant. As a safety measure, these T cells have been "programmed" with a "self-destruct switch" so that if, after they have been given to the patient, the T cells start to react against the tissues (called "graft versus host" disease, GVHD), the T cells can be destroyed.
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Lymphoma
- Myelodysplastic Syndromes
Interventions
BPX-501 dose 1Biological
Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
RimiducidDrug
Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
BPX-501 dose 2Biological
Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
BPX-501 dose 3Biological
Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
BPX-501 dose 4Biological
Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
SCTProcedure
all subjects will receive an alpha beta depleted donor transplant as part of treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- BPX-501 SafetyTime frame: 24 months
- Rimiducid SafetyTime frame: 24 months
- MTDTime frame: 24 months
- Immune ReconstitutionTime frame: 24 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Emory University Winship Cancer Institute
Atlanta, Georgia
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University Hospitals of Cleveland
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Baylor Sammons Cancer Center
Dallas, Texas
UT Southwestern Medical Center
Dallas, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.